

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of:

FOWLKES et al

Appln. No.: 09/050,359

Filed: March 31, 1998

For: IDENTIFICATION OF DRUGS
USING COMPLEMENTARY
COMBINATORIAL LIBRARIES



ART UNIT: 1627

Examiner: T.Wessendorf

Washington, D.C.

September 8, 2000

Atty.Docket: FOWLKES=4B

RECEIVED
SEP 12 2000
SEQUENCE CENTER 1600/2900
RESPONSE TO "SEQUENCE LISTING" REQUIREMENT

Honorable Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply mailed August
15, 2000, please amend the application as follows:

IN THE SPECIFICATION

emb Please substitute the attached Sequence Listing
pages 140-142 for those previously submitted.

REMARKS

Responsive to the communication dated August 15,
2000, applicants state as follows:

On page 29 of the specification, ten sequences
appear in which "GAX" denotes a codon encoding both Asp (D)

and Glu (E). According to the Genetic Code, Asp is encoded by GAT and GAC, while Glu is encoded by GAA and GAG. Thus, the X takes on the possible values T, C, A and G. The standard meaning of "N" is that all four of those bases are possible. Hence, while, in the sequence listing, SEQ ID NOs:1-10 should replace the "X" with an "N", there is no need for a "(ix) feature" to further particularize the meaning of that "N".

While we have corrected the Sequence Listing, we have left the sequences as they appear on page 29 intact as the "X" helps identify the scanning codon.

1. Applicants hereby submit the following:

[] a paper copy "Sequence Listing", complying with \$1.821(c), to be incorporated into the specification as directed above;

[XX] an amendment to the paper copy of the "Sequence Listing" submitted on July 14, 1998, the amendment being in the form of substitute sheets;

[XX] the Sequence Listing in computer readable form, complying with \$1.821(e) and \$1.824, including, if an amendment to the paper copy is submitted, all previously submitted data with the

all previously submitted data with the amendment incorporated therein;

[] pursuant to \$1.821(e), reference is made to the computer readable form filed on , in USSN , which presents the identical Sequence information, the use of which is now requested, in lieu of submitting a new computer readable form; and/or

[] a substitute computer readable form to replace one found to be damaged or unreadable.

[] 2. The description and claims have been amended to comply with \$1.821(d).

3. The undersigned attorney or agent hereby states as follows:

(a) this submission is not believed to include new matter [\$1.821(g)];

(b) the contents of the paper copy (as amended, if applicable) and the computer readable form of

the Sequence Listing, are believed to be the same [§1.821(f) and §1.825(b)];

(c) if the paper copy has been amended, the amendment is believed to be supported by the specification and is not believed to include new matter [§1.825(a)]; and

(d) if the computer readable form submitted herewith is a substitute for a form found upon receipt by the PTO to be damaged or unreadable, that the substitute data is believed to be identical to that originally filed [§1.825(d)].

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By: 

Iver P. Cooper
Registration No. 28,005

IPC:al
624 Ninth Street, N.W.
Washington, D.C. 20001
Telephone No.: (202) 628-5197
Facsimile No.: (202) 737-3528
F:\N\Nova\Fowlkes4B\Ltr\SequenceResponse.doc